Bafna Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 19, 2025
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals has informed the exchanges that its 30th Annual General Meeting will be held on September 19, 2025, at 10:00 AM via video conferencing, with CDSL providing e-voting services. The company has also submitted its Annual Report for FY 2024-2025 under SEBI LODR Regulation 34(1). Key financials show revenue declined marginally to ₹145.86 Cr from ₹152.47 Cr, while PAT fell sharply to ₹4.15 Cr from ₹7.35 Cr, partly due to a ₹2.15 Cr exceptional item from derecognition of an intangible asset. EBITDA stood at ₹13.92 Cr vs ₹14.63 Cr in the previous year. The AGM agenda includes adoption of financial statements, re-appointment of Ms. Akila Chintalapati Raju (retiring by rotation), appointment of Mr. Navin Kumar as Independent Director, re-appointment of two existing Independent Directors for second terms, appointment of M/s A.K. Jain & Associates as Secretarial Auditors for 5 years, and ratification of cost auditor remuneration of ₹75,000. The company has set a revenue target of ₹250 Cr+ by FY27 (~70% growth) and plans a 30% capacity expansion at Unit II by FY26.
This is primarily a routine AGM and annual report filing. Shareholders should note the notable decline in profitability (PAT down ~44% YoY) despite relatively stable revenues. The AGM will decide on key board appointments and the new secretarial auditor, and investors may want to review the full annual report and participate in e-voting on the resolutions.